Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

Full Abstract

OBJECTIVE:
Weight gain during insulin therapy can be a challenging problem in already overweight type 2 diabetes mellitus patients, affecting treatment compliance and long-term prognosis. The analogue insulin detemir has been reported to have a weight-sparing effect compared with other basal insulins. This pooled analysis investigated whether this potential advantage is related to body mass index (BMI) when insulin detemir is used as the basal component of basal-bolus therapy.

METHODS:
Data were pooled from two randomised, parallel group trials of 22 and 24 weeks' duration, in which 900 insulin-treated patients with type 2 diabetes mellitus had their treatment intensified to basal-bolus therapy. Patients received once- or twice-daily insulin detemir or neutral protamine Hagedorn (NPH) insulin in conjunction with insulin aspart or human soluble insulin at meal times.

RESULTS:
Patients treated with insulin detemir had minimal weight gain (mean <1 kg), regardless of their BMI at entry (estimated slope -0.032), whereas, in patients treated with NPH insulin, weight gain increased as baseline BMI increased (estimated slope 0.075, p = 0.025). Indeed, NPH insulin-treated patients with the largest BMI (>35 kg/m(2)) gained the most weight (mean of ~2.4 kg). In contrast, insulin detemir-treated patients with a BMI >35 kg/m(2) lost weight (mean of ~ -0.5 kg). Glycaemic control was similar with the two treatments.

CONCLUSION:
Insulin detemir may provide a clinical advantage in terms of reduced weight gain in the treatment of overweight patients with type 2 diabetes.

Learn Faster Today Improve your study skills

Author information

Author/s: Raslová, Katarina (K); Tamer, Soren Can (SC); Clauson, Per (P); Karl, Diane (D);

Affiliation: Metabolic Center Ltd and Slovak Medical University, Bratislava, Slovak Republic. katarina.raslova(-atsign-)nextra.sk

Journal and publication information

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal: Clinical drug investigation (Clin Drug Investig), published in New Zealand. (Language: eng)

Reference: 2007-; vol 27 (issue 4) : pp 279-85

Dates: Created 2007/03/15; Completed 2007/06/14;

PMID: 17358100, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Aged
Body Mass Index
Diabetes Mellitus, Type 2 - drug therapy; physiopathology
Double-Blind Method
Female

Humans
Insulin - analogs & derivatives; pharmacology; therapeutic use
Male
Middle Aged
Weight Gain - drug effects

Associated Chemicals: insulin detemir (0) ; Insulin (11061-68-0)

These are the highest related articles currently in the database:

See 100+ related articles.